Welcome to our dedicated page for Qualigen Therapeutics SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Qualigen Therapeutics, Inc. (historically NASDAQ: QLGN and now AIxCrypto Holdings, Inc. with symbol AIXC) provide detailed insight into the company’s transformation from a clinical-stage biotechnology issuer into a business that also emphasizes crypto, Web3, and decentralized AI activities. Through current reports on Form 8-K, registration statements on Form S-1, and proxy materials, investors can track how the company structures its financings, governs its operations, and discloses risks.
In its Form S-1 registration statement, the company outlines its current business mix: one early-clinical-stage program (QN-302), one preclinical Pan-RAS therapeutic program, and the C10 Cryptocurrency Asset Treasury with an 80% passive and 20% active allocation strategy to top cryptocurrencies. The S-1 also describes the terms of the Series B Convertible Preferred Stock, including conversion mechanics, voting rights, and the number of common shares that may be issued upon conversion, as well as the resale registration for those shares.
Multiple Form 8-K filings document the $41 million PIPE financing led by Faraday Future Intelligent Electric Inc., the Subscription Agreement and Registration Rights Agreement, and the Lead Investor Agreement that grants Faraday Future board nomination rights and participation rights in future financings. These filings also cover significant changes in senior management and the board of directors, the appointment and resignation of auditors, and Nasdaq correspondence regarding shareholder approval under Listing Rule 5635(b) and equity compliance under Listing Rule 5550(b)(1).
Additional filings, including the DEF 14A proxy statement, present the proposals submitted to stockholders, such as approval of the PIPE-related issuances and the 2025 Equity Incentive Plan. Name and ticker changes from Qualigen Therapeutics, Inc. (QLGN) to AIxCrypto Holdings, Inc. (AIXC) are recorded through amendments to the certificate of incorporation and related 8-K disclosures.
On Stock Titan’s filings page, users can review these documents as they are made available through EDGAR and use AI-powered summaries to understand complex items like preferred stock designations, treasury policies, and Nasdaq compliance matters. The page also surfaces key forms such as 10-Q and 10-K when filed, along with any future Form 4 insider transaction reports, to help readers analyze capital structure, governance developments, and the evolution of the company’s dual focus on therapeutics and AI × Web3 initiatives.
Qualigen Therapeutics, Inc. reported a net loss of $2.0 million for the quarter and $6.4 million for the nine months ended September 30, 2025, modestly higher than the prior year. The company’s balance sheet changed significantly after equity financings, with cash and cash equivalents rising to $38.8 million and total assets to $43.5 million, compared with $4.7 million of assets at year-end 2024.
In September 2025, Qualigen closed a $41.0 million Subscription Agreement led by Faraday Future, issuing common stock and new Series B convertible preferred stock. Up to $6.8 million of net proceeds are designated for existing debt repayment and current operations, while the remaining cash and contributed currency are reserved for establishing cryptocurrency treasury operations. Despite the capital raise, recurring losses, limited operating cash, and the early-stage nature of the new crypto strategy led management to conclude there is substantial doubt about the company’s ability to continue as a going concern over the next year.
Qualigen Therapeutics called a special stockholder meeting to seek approval for a recently closed private placement and related share issuances, conversion terms, and a new equity plan. Stockholders are asked to approve the Subscription Agreement and related transactions, including the prior sale of 337,432 shares of common stock and 39,943 shares of Series B Convertible Preferred Stock, and to allow conversion-related issuances above the Nasdaq 19.99% cap.
The Offering totaled $41,000,000 in cash. Series B Preferred carries a $1,000 stated value and is convertible at $2.246 per share after stockholder approval, subject to beneficial ownership limits. The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund operations, with the remainder and contributed currency for establishing cryptocurrency treasury operations.
Stockholders will also vote on a 2025 Equity Incentive Plan equal to 20% of common stock outstanding after the Offering, with a 10% annual evergreen increase through 2046, and on the ability to adjourn the meeting to solicit additional proxies if needed.
Qualigen Therapeutics is asking stockholders to approve the private Offering of $41,000,000 in equity that included 337,432 shares of Common Stock and 39,943 shares of newly created Series B Convertible Preferred Stock.
The Offering closed on September 29, 2025; Common Stock was priced at $2.246 per share and each share of Series B Stock has a $1,000 stated value and converts into Common Stock at a conversion price of $2.246 subject to shareholder approval to permit conversions above a 19.99% exchange cap. The Company plans to use up to $6,800,000 of net proceeds to repay debt and fund operations, with the remainder allocated to establish cryptocurrency treasury operations. Stockholder approval is also requested for a 2025 Equity Incentive Plan with a share reserve equal to 20% of Common Stock outstanding after the Offering and an evergreen 10% annual increase through 2036.
Qualigen Therapeutics reports several governance and audit changes. Its prior auditor, WithumSmith+Brown, resigned effective October 1, 2025, ending engagements for the September 30, 2025 quarterly review and the December 31, 2025 year-end audit. Withum’s report on the year ended December 31, 2024 included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, but otherwise was not adverse or qualified, and the company states there were no disagreements or other reportable events beyond previously disclosed material weaknesses in internal control over financial reporting.
The Audit Committee approved Macias Gini & O’Connell LLP as new independent auditor for the 2025 year-end audit and specified interim reviews through September 30, 2026, subject to client acceptance procedures. Effective October 2, 2025, the company appointed Jiawei Wang as Co‑Chief Executive Officer and Koti Meka as Chief Financial Officer, and added three new directors, who also joined key board committees. Three existing directors resigned in connection with a recent private placement, with the company stating these departures were not due to disagreements.
Qualigen Therapeutics (QLGN) closed a $41,000,000 private placement on September 29, 2025, selling 337,432 shares of common stock at $2.246 and 17,783 shares of Series B Convertible Preferred Stock at a $1,000 stated value. The Series B converts into common at a $2.246 conversion price after Stockholder Approval under Nasdaq Rule 5635, with allocations capped at 19.99% ownership per investor at closing.
The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund current operations, with the balance of cash proceeds and contributed currency for establishing cryptocurrency treasury operations. Qualigen agreed to file a resale registration within 45 days of closing and target effectiveness 45 days thereafter (or 60 days if fully reviewed). Univest Securities will receive a 5.5% cash fee, warrants equal to 6% of securities sold at a $2.47 exercise price, and up to $150,000 in expenses. The Lead Investor, Faraday Future Intelligent Electric Inc., secured board designation rights; board changes include appointing Jiawei Wang as Co‑CEO and Koti Meka as CFO, alongside three director resignations.
Qualigen Therapeutics, Inc. reported that its Board of Directors appointed Kevin Chen as an independent director, effective September 26, 2025. As of this appointment, he has not yet been assigned to any Board committees. Chen is currently Chief Economist and CIO of Horizon Financial and serves on several public company boards, including CurrenC Group, Australian Oilseeds Investments, Scage Future and Capitan Investment Ltd. His background includes senior investment roles at Credit Agricole/Amundi Asset Management and Morgan Stanley, as well as academic positions at New York University and other institutions.
Qualigen Therapeutics entered into a private placement on September 19, 2025, under which investors, led by Faraday Future Intelligent Electric Inc., agreed to purchase $41,000,000 of common stock and new Series B convertible preferred stock. Common shares are priced at $2.246 and Series B shares at $1,000 each, with Series B convertible into common at a $2.246 conversion price after required stockholder approval under Nasdaq Rule 5635. The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund current operations, with remaining cash and contributed currency earmarked for cryptocurrency treasury operations.
Univest Securities will receive a 5.5% cash fee on gross proceeds, warrants equal to 6% of securities sold exercisable at $2.47 per share, and up to $150,000 in expense reimbursement. A Lead Investor Agreement gives Faraday Future board representation rights while it owns at least 5% of outstanding common stock, including the appointment of Jiawei Wang as Co‑CEO and Koti Meka as CFO. An advisory firm will receive approximately 60,257 common shares, described as 5% of outstanding common stock following the closing.
Qualigen Therapeutics, Inc. filed an S-1 registration statement seeking to offer additional common stock under the Nasdaq Capital Market ticker QLGN. The document lists a post-offering common share count of 4,909,932 shares assuming all offered shares are sold and shows existing selling stockholders controlling a combined 3,214,292 shares.
The filing discloses recent financing activity: issuance of 32,092 shares to Alpha in lieu of redemption payments at a weighted average price of $14.47 per share; a $550,000 8% convertible debenture to Alpha issued for $500,000 convertible at $30.56 per share with an attached 18,000‑share warrant at $13.00; and a $1,100,000 8% convertible debenture to Chen issued for $1,000,000 convertible at $30.56 with a 36,001‑share warrant at $13.00. Both debentures and warrants include a 9.99 beneficial ownership blocker and purchasers waived certain participation and acceleration rights relating to this offering. The filing also notes Alpha completed conversion of a prior $3,300,000 debenture into 24,379 shares on July 5, 2024.
Qualigen Therapeutics, Inc. filed a current report describing an amendment to its secured borrowing arrangement with Marizyme, Inc. On September 15, 2025, the company entered into Amendment No. 1 to its Amended and Restated Secured Demand Promissory Note dated August 21, 2025.
The amendment corrects the note’s maturity date to August 21, 2026, increases the advance and principal amount by $75,000, and results in a revised outstanding principal balance of $4,526,462.18. The additional advance accrues interest at the same rate set in the existing note, and the company’s obligations remain secured under the existing Security Agreement. The amendment also triggers disclosure of a direct financial obligation under the relevant reporting item.